Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis.

David StahlCarola Tho PeschCarolin BrückRuth L EsserJan ThieleVeronica Di CristanzianoDavid M Kofler

Published in: RMD open (2022)

Concomitant methotrexate increases the risk of an insufficient humoral immune response to SARS-CoV-2 vaccination in elderly patients with RA. Pausing methotrexate during the third vaccination period may be considered for this group of patients.

Keyphrases

sars cov
immune response
high dose
end stage renal disease
respiratory syndrome coronavirus
ejection fraction
middle aged
newly diagnosed
chronic kidney disease
rheumatoid arthritis
prognostic factors
peritoneal dialysis
stem cells
systemic sclerosis
cell therapy
smoking cessation